Education
About Us
Working with TipRanks
Follow Us
Cardiol Therapeutics (CRDL)
NASDAQ:CRDL
CRDL Stock Chart & Stats
$1.01
-$0.03(-2.19%)
At close: 4:00 PM EST
$1.01
-$0.03(-2.19%)
Day’s Range― - ―
52-Week Range$0.77 - $1.59
Previous Close$1.33
Volume248.87K
Average Volume (3M)701.45K
Market Cap
$112.77M
Enterprise Value$142.63M
Total Cash (Recent Filing)$11.62M
Total Debt (Recent Filing)$134.20K
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Apr 01, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding111,680,084
10 Day Avg. Volume564,759
30 Day Avg. Volume701,452
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)5.35
Price to Sales (P/S)0.00
P/FCF Ratio-5.28
Enterprise Value/Market Cap1.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.60K
Enterprise Value/Ebitda-3.97
Forecast
1Y Price Target
$9.00Price Target Upside791.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.39
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Biomarker ImprovementsESC publication of the ARCHER study demonstrates statistically significant reductions in left ventricular mass, indicating reduced cardiac inflammation and edema linked to improved myocardial structure and function.
Competitive Differentiation And PartneringFailure of a major relaxin-based competitor underscores limits of vasodilatory strategies and increases appeal of CRD-38's myocardial biology approach to potential partners focused on inflammation, fibrosis, and mitochondrial preservation.
Safety And Tolerability ProfileDetailed adverse-event data indicate CardiolRx is well tolerated, with gastrointestinal events consistent for the therapy class and a lower incidence of asthenia versus placebo, supporting chronic cardiac use.
Bears Say
Imaging Quality LimitationsImaging quality issues reduced the analyzable patient set in ARCHER, weakening statistical power and creating uncertainty about the formal significance of trial findings.
Market Valuation And PerceptionCurrent market capitalization appears to assign little value to ARCHER's positive signals, which could hinder fundraising dynamics and limit negotiating leverage with potential collaborators.
Primary Endpoint Statistical PowerA smaller analyzable sample for extracellular volume measurements materially reduced power for the primary endpoint, raising the risk that results could be viewed as inconclusive by regulators or partners.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was $0.77 and its highest was $1.59 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is $112.77M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 27 days.
How were Cardiol Therapeutics’s earnings last quarter?
Cardiol Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.088 earnings per share for the quarter, missing the consensus estimate of -$0.073 by -$0.015.
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.08.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 111,680,084 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Cardiol Therapeutics reported an EPS of -$0.088 in its last earnings report, missing expectations of -$0.073. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (791.09% Upside)
$9.00 (791.09% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.90%
12-Months-Change
Fundamentals
Return on Equity
-271.56%
Trailing 12-Months
Asset Growth
-24.01%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
$9.00
▲(791.09% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―
Ownership Overview
2.32% Insiders
0.05% Mutual Funds
6.22% Other Institutional Investors
90.09% Public Companies and
Individual Investors